BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference

  Presentation highlights expanded pre-clinical data supporting the development of XMT-1536 in a broad population of patients with ovarian cancer.

  October 30, 2017

   · 

  5 min read
• Trading of Össur Shares to be Concentrated on Nasdaq Copenhagen From 6 December 2017

  By concentrating the trading on one market, trading liquidity of Össur shares will increase and the price formation will be more effective for the benefit of all shareholders.

  October 30, 2017

   · 

  2 min read
• Drug Development

  BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia

  The approval will enable BIOPHYTIS to begin the SARA-INT interventional study in five clinical centers in the United States.

  October 30, 2017

   · 

  6 min read
• Make Sure Moisture Analysis Is Accurate With New White Paper From METTLER TOLEDO

  October’s e-calendar offer from METTLER TOLEDO will help users learn to ensure reliable halogen moisture analyzer results through an easy, 10-minute routine test.

  October 30, 2017

   · 

  1 min read
• Policy

  INSYS Therapeutics to Record a Minimum Liability for Department of Justice Settlement in Q3 2017

  As of Sept. 30, 2017, $150 million has been accrued, which represents our best estimate of the minimum liability exposure we expect to pay over five years.

  October 30, 2017

   · 

  3 min read
• Business

  INSYS Therapeutics Announces Resignation of Patrick P. Fourteau From Board of Directors

  Mr. Fourteau cited personal reasons for stepping down from the board.

  October 30, 2017

   · 

  2 min read
• OrbusNeich’s COMBO Dual Therapy Stent Demonstrates Non-Inferiority vs the Market Leading XIENCE™ Everolimus Eluting Stent

  The results showed that the overall incidence of the primary endpoint target vessel failure was lower than the original estimated 9.0%, with 7.0% in the COMBO group vs 4.2% in the Xience group at 12 months, thereby meeting the non-inferiority requirement

  October 30, 2017

   · 

  5 min read
• Business

  Toyota Signs Licensing Agreement with Kazusa DNA Research Institute, Eurofins Genomics, and GeneBay for GRAS-Di DNA Analysis Technology

  Toyota’s unique GRAS-Di(1) DNA analysis technology that can dramatically accelerate selective breeding.

  October 30, 2017

   · 

  5 min read
• Business

  INSYS Therapeutics Founder Dr. John N. Kapoor Steps Down from Board of Directors

  The founder was charged with bribing doctors to prescribe opioid painkillers last week.

  October 30, 2017

   · 

  2 min read
• Crescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting

  Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. , today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 3-8, 2017 in San Diego,

  October 30, 2017

   · 

  4 min read